GHK-Cu: What the Evidence Actually Shows

Search "GHK-Cu" and the results split into two products sold under one name: a copper-binding tripeptide added to anti-aging face creams and sold over the counter by dozens of skincare brands, and a compounded, injectable version marketed for tendon repair, hair regrowth, and systemic anti-aging effects. Unlike BPC-157 and TB-500 — the two other peptides this site has reviewed in this format — GHK-Cu's topical form genuinely does have controlled human trials behind it, going back more than three decades. That's the detail most marketing for the injectable version gets right. It's also where that marketing quietly changes the subject: a direct PubMed search filtered to "clinical trial" and "randomized controlled trial" publication types returns exactly three results for GHK-Cu, ever. Two are human trials — both topical. The third is an animal trial, also topical. Zero are injectable, in humans or otherwise. This article traces both evidence records to their source, because the gap between them is the actual story here.

What GHK-Cu actually is, and its proposed mechanism

GHK-Cu is the copper(II) complex of a three-amino-acid peptide, glycyl-L-histidyl-L-lysine (GHK) — a molecule naturally present in human plasma, where it binds copper and is reported to decline in concentration with age⁹. That's a real point of chemical distinction from BPC-157 and TB-500, both synthetic fragments with no natural counterpart circulating in the body at the concentrations sold. The independent literature attributes a broad set of proposed actions to GHK and GHK-Cu: stimulation of collagen, elastin, and glycosaminoglycan synthesis, increased fibroblast activity, and promotion of new blood-vessel and nerve growth¹. A separate orthopedic review groups GHK-Cu with BPC-157 and TB-500 as wound-healing peptides that "promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation" — the same broad pathway family invoked for its two site-mates — while stating plainly that "there is a current lack of clinical trials²." Those are real, published, mechanistically coherent pathways. They are also, as in this site's BPC-157 and TB-500 reviews, drawn mostly from cell-culture and animal work — a proposed explanation for why GHK-Cu might work, not a demonstration that it does, in either the topical or the injectable use case.

What the topical evidence actually shows

This is where GHK-Cu genuinely differs from BPC-157 and TB-500: real controlled human trials exist. The two human trials PubMed's own clinical-trial filter turns up are decades old, small, and worth reading in full rather than taking on faith from a product label:

• •Venous stasis ulcers, 1992. A prospective, randomized, evaluator-blinded trial at a US wound-care center: 86 evaluable patients were assigned to one of three topical arms — silver sulfadiazine 1% cream, a 0.4% tripeptide-copper-complex (GHK-Cu) cream, or an inert vehicle placebo. The result, read directly from the paper: silver sulfadiazine "proved to statistically reduce the ulcer size" compared with both other arms, while "there was no difference between the latter two treatments" — the GHK-Cu cream performed no better than plain placebo in this trial³.
• •CO2 laser-resurfaced skin, 2006. A randomized trial in 13 patients who completed post-treatment skincare regimens with or without a GHK-Cu product after facial CO2 laser resurfacing, evaluated with computer-analyzed photography and blinded raters. The objective result: "no statistically significant differences between groups" in how quickly erythema resolved, and "no significant improvement in wrinkles or overall skin quality" by objective measure. The one place a difference showed up was a patient-completed questionnaire, where satisfaction with overall skin quality was significantly higher in the GHK-Cu group (P=.04)⁴ — a real, reported finding, and also a subjective one that the same paper's own objective measures didn't confirm.

The third result in that clinical-trial-filtered search isn't a human study at all: a 2006 veterinary trial testing the same topical copper-tripeptide complex on open wounds in rabbits.

That is the entire controlled-trial record for GHK-Cu, topical or otherwise, as of this review: two small human RCTs, decades old, with a combined enrollment under 100 people — and neither found the tested GHK-Cu product to beat its comparator on the trial's own primary endpoint. A 2025 formulation-science review reaches a related conclusion from the cosmetic-industry side of the same literature, despite GHK-Cu's status as a widely marketed anti-wrinkle ingredient: "there is a surprising absence of clinical studies using them," referring to GHK-Cu and its palmitoylated derivative¹. That review attributes part of the gap to a genuine formulation obstacle rather than only a marketing one: GHK-Cu is hydrophilic and has documented difficulty penetrating the skin's outer barrier at an active concentration without a specialized delivery method — a route-specific pharmacology problem, independent of whether the underlying cell-culture mechanism is real¹.

None of that means topical GHK-Cu does nothing. The cell-culture and rodent literature behind it is real and cited above, and a currently recruiting Phase 2 trial — sponsored by Hudson Biotech, the same company running the BPC-157 hamstring-strain trial cited in this site's BPC-157 review — is testing a 0.1% topical GHK-Cu gel against a vehicle placebo on standardized punch-biopsy wounds in 60 participants, with no results reported yet¹³. It means the actual controlled human evidence for topical GHK-Cu, checked directly rather than assumed from how often it shows up on an ingredient label, is thin, old, and mixed on its own primary endpoints — genuinely more than BPC-157 or TB-500 have in humans, but not the settled case its cosmetic marketing implies either.

What the injectable/systemic evidence actually shows

Narrow the same question to the injectable, systemic use case this site's GHK-Cu calculator exists for, and the record drops from thin to essentially empty. Neither human trial above involved an injection. A broader PubMed search for GHK-Cu combined with "systemic," "subcutaneous," or "intraperitoneal" returns 12 results, and every one is an animal or cell-culture study — no human study appears at all. A 2026 orthopedic-focused primer that specifically evaluated GHK-Cu for the musculoskeletal use case it's often sold for states the gap directly: "GHK-Cu showed promise in wound healing and anti-inflammatory effects, but no clinical data support its use for musculoskeletal conditions⁵."

The animal literature that does exist is scattered across disease models with little relationship to each other or to how injectable GHK-Cu is actually marketed:

• •Tendon/ligament repair, rats, 2015. The one located study that actually tests injected GHK-Cu for the joint/tendon-repair claim it's most often sold on: 72 rats underwent ACL reconstruction and received weekly intra-articular GHK-Cu injections, at two doses, against a saline control, for four weeks. At 6 weeks, the treated groups showed measurably less knee laxity (p=0.009) and, at the lower dose, higher graft stiffness (p=0.026) than saline. By 12 weeks — six weeks after the injections stopped — none of those differences remained significant, and the study's own conclusion states plainly that the benefit "could not last as treatment discontinued⁶." A real, controlled, dose-ranging animal finding, with its own reported result being that the effect faded once dosing stopped.
• •Lung disease, mice, 2020 and 2022. Two independent pulmonology research groups injected GHK-Cu intraperitoneally into mice with chemically induced pulmonary fibrosis and cigarette-smoke-induced emphysema, respectively, and both reported reduced inflammatory and oxidative-stress markers compared to untreated diseased mice⁷⁸. Real, peer-reviewed, dose-ranging preclinical findings — in mouse lung-disease models with no direct connection to the tendon-repair or anti-aging claims injectable GHK-Cu is actually sold on.
• •Cognitive aging, mice, 2026 — not yet peer-reviewed. A university research group tested intraperitoneal against intranasal GHK-Cu in aged mice on a spatial-learning task. This result comes from a preprint posted to Research Square, not a published, peer-reviewed journal, and this article flags that status explicitly rather than treating it as settled: intranasal dosing "improved escape latency across Trials 2-4 in both sexes," while intraperitoneal dosing "produced a transient improvement in males during Trial 2... without sustained effects or improvement in females⁹" — meaning even within this one unreviewed preprint, the injectable route underperformed the non-injectable one.

Put together: the entire published evidence base for injected or systemically dosed GHK-Cu, across every claimed use, is a handful of animal studies scattered across unrelated disease models — one of which hasn't cleared peer review — plus a single rat orthopedic study whose own measured benefit faded once the injections stopped. No published human trial of injectable or systemic GHK-Cu exists, and a ClinicalTrials.gov search for "GHK-Cu" and "copper tripeptide" turns up exactly two relevant records: the recruiting topical-gel trial described above and a not-yet-recruiting study of a wearable patch's effect on blood GHK levels. Neither is an injectable study, and no injectable/systemic GHK-Cu trial of any kind is currently registered.

The current FDA and compounding status for injectable GHK-Cu

DailyMed, the National Library of Medicine's official archive of FDA-approved drug labeling, returns the identical result set today as it did the day this site's GHK-Cu calculator page was last reviewed: three listings for "copper peptide" (two face serums, one hair-growth serum) and one more for "GHK" (a sunscreen) — every one a topical, over-the-counter cosmetic product listing copper tripeptide-1 as one ingredient among several, not an FDA-reviewed drug application¹². There is no FDA-approved GHK-Cu drug product of any kind, injectable or otherwise, and there never has been.

Injectable GHK-Cu's compounding status specifically has moved, and the move is recent and only partial. FDA's interim Section 503A bulk-substances list has, since 2023, split GHK-Cu by route of administration: non-injectable (topical/oral) GHK-Cu sits in Category 1, no intended enforcement action; injectable GHK-Cu sat in Category 2, the significant-safety-risk tier, citing immunogenicity and impurity concerns. On April 15, 2026, injectable GHK-Cu was one of twelve peptides FDA removed from Category 2 — the same action that also removed BPC-157 and TB-500 — via withdrawal of the original nomination, not an FDA safety finding¹¹. FDA's own PCAC meeting page for its July 23-24, 2026 hearing, fetched live for this review, lists exactly seven bulk drug substances discussed at that meeting — BPC-157, KPV, TB-500, and MOTs-C on July 23; Emideltide, Semax, and Epitalon on July 24 — and GHK-Cu is not among them¹⁰. FDA has instead said it will consult PCAC on injectable GHK-Cu at a separate meeting to be held before the end of February 2027, alongside four other peptides — LL-37, DiHexa, Melanotan II, and PEG-MGF¹¹. As of this review, that meeting has not happened. Injectable GHK-Cu is, in that specific sense, a full step further from resolution than BPC-157 or TB-500: both of those have already had their PCAC hearing and vote (recommended for the 503A Bulks List, pending further FDA rulemaking); injectable GHK-Cu has not yet had its hearing at all.

What this means if you're considering an injectable compounded GHK-Cu product

Put the pieces together and the honest picture is this: GHK-Cu is a real, naturally occurring molecule with a genuinely more substantial human evidence base than BPC-157 or TB-500 — but that entire advantage belongs to the topical form, and even there it amounts to two small, decades-old RCTs that didn't beat their own comparator on the trial's primary measure. The injectable, systemic use case this site's calculator exists to help with is a different evidence picture entirely: a handful of animal studies scattered across lung disease and cognitive-aging models that have nothing to do with tendon repair or systemic anti-aging, one rat orthopedic study whose measured benefit faded once dosing stopped, zero published human trials, and a compounding-legal status one procedural step behind BPC-157 and TB-500's own unresolved timelines.

Concretely, for a reader weighing a compounded injectable GHK-Cu product against a topical skincare one: these are not the same evidence claim wearing two different delivery methods. The topical literature already documents a real, route-specific pharmacology problem — GHK-Cu's difficulty crossing the skin barrier without a specialized carrier — and that same route-dependence cuts the other way too: nothing about how a molecule behaves in a face cream predicts what an intramuscular or subcutaneous dose does systemically, and nothing in the injectable animal studies above validates the skincare claim either. Our GHK-Cu reconstitution calculator does the vial-to-syringe arithmetic on the injectable, compounded form specifically — and, as this review confirms independently, there remains no FDA-approved product, no agency-set dosing standard, and no completed injectable human trial to check that arithmetic against. Readers weighing BPC-157 or TB-500 alongside GHK-Cu — often marketed together in the same "healing stack" — can find BPC-157's own evidence record here and TB-500's here.